Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Vanda Pharmaceuticals (VNDA)

Vanda Pharmaceuticals (VNDA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences PR Newswire - Thu May 7, 5:44PM CDT

WASHINGTON , May 7, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate at the following upcoming investor conferences in May...

VNDA : 6.43 (+0.16%)
Vanda: Q1 Earnings Snapshot AP - Wed May 6, 3:07PM CDT

Vanda: Q1 Earnings Snapshot

VNDA : 6.43 (+0.16%)
Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results PR Newswire - Wed May 6, 3:01PM CDT

WASHINGTON , May 6, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the first quarter ended March 31, 2026.

VNDA : 6.43 (+0.16%)
Vanda Pharmaceuticals: Can Prescription Momentum Justify the Valuation Before Bysanti's Regulatory Verdict? Barchart - Tue May 5, 4:39PM CDT

Barchart Research What to Expect from VNDA Earnings VNDA Generated May 5, 2026 Current Price $7.39 EPS Estimate $$-0.53 Consensus Rating Moderate Buy Average Move 7.71% Vanda Pharmaceuticals: Can Prescription...

VNDA : 6.43 (+0.16%)
Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years PR Newswire - Mon May 4, 7:00AM CDT

WASHINGTON , May 4, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that NEREUS™ (tradipitant) is now commercially available across the United States for...

VNDA : 6.43 (+0.16%)
Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years PR Newswire - Fri May 1, 3:35PM CDT

WASHINGTON , May 1, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that NEREUS™ (tradipitant) is now commercially available across the United States for...

VNDA : 6.43 (+0.16%)
Vanda Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026 PR Newswire - Wed Apr 29, 3:30PM CDT

Conference Call and Webcast to Follow

VNDA : 6.43 (+0.16%)
Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence PR Newswire - Tue Apr 28, 6:12PM CDT

WASHINGTON , April 28, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the publication of the original research article titled "Efficacy and Safety of Imsidolimab...

ANAB : 62.69 (-4.41%)
VNDA : 6.43 (+0.16%)
Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors PR Newswire - Wed Apr 22, 4:13PM CDT

WASHINGTON , April 22, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the appointment of Charles Duncan, Ph.D. to its Board of Directors effective April 22,...

VNDA : 6.43 (+0.16%)
Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines PR Newswire - Thu Apr 9, 10:02AM CDT

WASHINGTON , April 9, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today highlighted a legislative proposal contained in the FDA's FY 2027 Congressional Budget Justification....

VNDA : 6.43 (+0.16%)

Barchart Exclusives

Yield Is No Longer King: What These 5 Dividend ETFs Are Telling Investors Barchart - Wed May 13, 6:30PM CDT
Dividend investing has changed, and yield is misunderstood or misused by many investors. Let's take a closer look at 5 ETFS and discuss what dividend investors should know. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.